Adenosine and related drugs in brain diseases: Present and future in clinical trials

Current Topics in Medicinal Chemistry

Volumn 11, Issue 8, 2011, Pages 1087-1101

  Lopes, Luísa V ^a   Sebastião, Ana M ^a   Ribeiro, Joaquim A ^a  

^a UNIVERSITY OF LISBON   (Portugal)

Author keywords

Adenosine; Brain; Caffeine; Clinical trials; Drug addiction; Human; Neurodegenerative diseases; Psychiatric disorders

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 CHLORO 6 N CYCLOPENTYLADENOSINE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 4 AMINOBUTYRIC ACID; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE RECEPTOR; BIPERIDEN; CAFFEINE; DIPYRIDAMOLE; ISTRADEFYLLINE; LIGAND; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; PSB603; UNCLASSIFIED DRUG; ZM24138;

ACUTE STRESS DISORDER; ANXIETY; ANXIETY DISORDER; ARTICLE; BRAIN DISEASE; CLINICAL TRIAL (TOPIC); COCAINE DEPENDENCE; COGNITION; DRUG DEPENDENCE; DRUG METABOLISM; EPILEPSY; EXTRACELLULAR SPACE; HUMAN; HUNTINGTON CHOREA; MEMORY; MEMORY DISORDER; MENTAL DISEASE; NERVE DEGENERATION; PANIC; PARKINSON DISEASE; PATHOLOGY; PROTEIN SECRETION; SCHIZOPHRENIA; SYNAPSE;

ADENOSINE; ANIMALS; ASTROCYTES; BRAIN; BRAIN DISEASES; CLINICAL TRIALS AS TOPIC; COGNITION; FORECASTING; HUMANS; MEMORY; MICE; MICE, KNOCKOUT; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTRANSMITTER AGENTS; PURINERGIC P1 RECEPTOR AGONISTS; PURINERGIC P1 RECEPTOR ANTAGONISTS; RATS; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 79954503213     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802611795347591     Document Type: Article

References (203)

1. Arch, J. R.; Newsholme, E. A. Activities and some properties of 5'-nucleotidase, adenosine kinase and adenosine deaminase in tissues from vertebrates and invertebrates in relation to the control of the concentration and the physiological role of adenosine. Biochem. J. 1978, 174, 965-977.
2. Van den Berghe, G.; Bontemps, F.; Vincent, M. F.; Van den Bergh, F. The purine nucleotide cycle and its molecular defects. Prog. Neurobiol. 1992, 39, 547-561.
3. Stone, T. W.; Ceruti, S.; Abbracchio, M. P. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb. Exp. Pharmacol. 2009, 535-587.
4. Dunwiddie, T. V.; Masino, S. A. The role and regulation of adenosine in the central nervous system. Annu. Rev. Neurosci. 2001, 24, 31-55.
5. Fredholm, B. B.; Battig, K.; Holmen, J.; Nehlig, A.; Zvartau, E. E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 1999, 51, 83-133.
6. Ginsborg, B. L.; Hirst, G. D. The effect of adenosine on the release of the transmitter from the phrenic nerve of the rat. J. Physiol. 1972, 224, 629-645.
7. Ribeiro, J. A.; Walker, J. The effects of adenosine triphosphate and adenosine diphosphate on transmission at the rat and frog neuromuscular junctions. Br. J. Pharmacol. 1975, 54, 213-218.
8. Sattin, A.; Rall, T. W. The effect of adenosine and adenine nucleotides on the cyclic adenosine 3', 5'-phosphate content of guinea pig cerebral cortex slices. Mol. Pharmacol. 1970, 6, 13-23.
9. Pull, I.; McIlwain, H. Output of (14C)adenine nucleotides and their derivatives from cerebral tissues. Tetrodotoxin-resistant and calcium ion-requiring components. Biochem. J. 1973, 136, 893-901.
10. Sebastião, A. M.; Ribeiro, J. A. Adenosine receptors and the central nervous system. Handb. Exp. Pharmacol. 2009, 471-534.
11. Fredholm, B. B. Adenosine and neuroprotection. Int. Rev. Neurobiol. 1997, 40, 259-280.
12. Phillips, E.; Newsholme, E. A. Maximum activities, properties and distribution of 5' nucleotidase, adenosine kinase and adenosine deaminase in rat and human brain. J. Neurochem. 1979, 33, 553-558.
13. Nagata, H.; Mimori, Y.; Nakamura, S.; Kameyama, M. Regional and subcellular distribution in mammalian brain of the enzymes producing adenosine. J. Neurochem. 1984, 42, 1001-1007.
14. Meghji, P.; Pearson, J. D.; Slakey, L. L. Regulation of extracellular adenosine production by ectonucleotidases of adult rat ventricular myocytes. Am. J. Physiol. 1992, 263, H40-7.
15. Wu, P. H.; Barraco, R. A.; Phillis, J. W. Further studies on the inhibition of adenosine uptake into rat brain synaptosomes by adenosine derivatives and methylxanthines. Gen. Pharmacol. 1984, 15, 251-254.
16. Nagy, A. K.; Houser, C. R.; Delgado-Escueta, A. V. Synaptosomal ATPase activities in temporal cortex and hippocampal formation of humans with focal epilepsy. Brain Res. 1990, 529, 192-201.
17. Hertz, L.; Matz, H. Inhibition of adenosine deaminase activity reveals an intense active transport of adenosine into neurons in primary cultures. Neurochem. Res. 1989, 14, 755-760.
18. Ballarin, M.; Fredholm, B. B.; Ambrosio, S.; Mahy, N. Extracellular levels of adenosine and its metabolites in the striatum of awake rats: inhibition of uptake and metabolism. Acta Physiol. Scand. 1991, 142, 97-103.
19. Zimmermann, H. 5'-Nucleotidase: molecular structure and functional aspects. Biochem. J. 1992, 285 (Pt 2), 345-365.
20. Sciotti, V. M.; Van Wylen, D. G. Increases in interstitial adenosine and cerebral blood flow with inhibition of adenosine kinase and adenosine deaminase. J. Cereb. Blood Flow Metab. 1993, 13, 201-217.
21. Olsson, R. A.; Pearson, J. D. Cardiovascular purinoceptors. Physiol. Rev. 1990, 70, 761-845.
22. Wall, M.; Dale, N. Activity-dependent release of adenosine: a critical re-evaluation of mechanism. Curr. Neuropharmacol. 2008, 6, 329-337.
23. Dunwiddie, T. V.; Diao, L. Extracellular adenosine concentrations in hippocampal brain slices and the tonic inhibitory modulation of evoked excitatory responses. J. Pharmacol. Exp. Ther. 1994, 268, 537-545.
24. Andine, P.; Thordstein, M.; Kjellmer, I.; Nordborg, C.; Thiringer, K.; Wennberg, E.; Hagberg, H. Evaluation of brain damage in a rat model of neonatal hypoxic-ischemia. J. Neurosci. Methods 1990, 35, 253-260.
25. Dux, E.; Fastbom, J.; Ungerstedt, U.; Rudolphi, K.; Fredholm, B. B. Protective effect of adenosine and a novel xanthine derivative propentofylline on the cell damage after bilateral carotid occlusion in the gerbil hippocampus. Brain Res. 1990, 516, 248-256.
26. Cunha, R. A.; Sebastiao, A. M. Adenosine and adenine nucleotides are independently released from both the nerve terminals and the muscle fibres upon electrical stimulation of the innervated skeletal muscle of the frog. Pflugers Arch. 1993, 424, 503-510.
27. Schubert, P.; Rudolphi, K. A.; Fredholm, B. B.; Nakamura, Y. Modulation of nerve and glial function by adenosine--role in the development of ischemic damage. Int. J. Biochem. 1994, 26, 1227-1236.
28. Sebastião, A. M.; Ribeiro, J. A. On the adenosine receptor and adenosine inactivation at the rat diaphragm neuromuscular junction. Br. J. Pharmacol. 1988, 94, 109-120.
29. Nimit, Y.; Skolnick, P.; Daly, J. W. Adenosine and cyclic AMP in rat cerebral cortical slices: effects of adenosine uptake inhibitors and adenosine deaminase inhibitors. J. Neurochem. 1981, 36, 908-912.
30. Agbanyo, F. R.; Vijayalakshmi, D.; Craik, J. D.; Gati, W. P.; McAdam, D. P.; Asakura, J.; Robins, M. J.; Paterson, A. R.; Cass, C. E. 5'-S-(2-aminoethyl)-N6-(4-nitrobenzyl)-5'-thioadenosine (SAENTA), a novel ligand with high affinity for polypeptides associated with nucleoside transport. Partial purification of the nitrobenzylthioinosine-binding protein of pig erythrocytes by affinity chromatography. Biochem. J. 1990, 270, 605-614.
31. Bender, A. S.; Wu, P. H.; Phillis, J. W. The characterization of [3H] adenosine uptake into rat cerebral cortical synaptosomes. J. Neurochem. 1980, 35, 629-640.
32. Thampy, K. G.; Barnes, E. M., Jr. Adenosine transport by primary cultures of neurons from chick embryo brain. J. Neurochem. 1983, 40, 874-879.
33. Geiger, J. D.; Johnston, M. E.; Yago, V. Pharmacological characterization of rapidly accumulated adenosine by dissociated brain cells from adult rat. J. Neurochem. 1988, 51, 283-291.
34. Geiger, J. D.; Fyda, D. M. Adenosine transport in nervous system tissues. In Adenosine in the nervous system; Stone, T.; Ed.; Academic Press: London, 1981; 1-23.
35. Plagemann, P. G.; Wohlhueter, R. M. The hypoxanthine transporter of Novikoff rat hepatoma cells exhibits directional symmetry and equal mobility when empty or substrate-loaded. Biochim. Biophys. Acta 1982, 688, 505-514.
36. Paterson, A. R.; Lau, E. Y.; Dahlig, E.; Cass, C. E. A common basis for inhibition of nucleoside transport by dipyridamole and nitrobenzylthioinosine? Mol. Pharmacol. 1980, 18, 40-44.
37. Gu, J. G.; Kala, G.; Geiger, J. D. [3H]adenosine transport in synaptoneurosomes of postmortem human brain. J. Neurochem. 1993, 60, 2232-2237.
38. Di Iorio, P.; Ballerini, P.; Ciccarelli, R.; Tacconelli, L.; Caciagli, F. Sodium and calcium dependence of purine release from rat cerebral cortical slices. Pharmacol. Res. Commun. 1988, 20, 511-525.
39. Mosqueda-Garcia, R.; Tseng, C. J.; Appalsamy, M.; Beck, C.; Robertson, D. Cardiovascular excitatory effects of adenosine in the nucleus of the solitary tract. Hypertension 1991, 18, 494-502.
40. Sebastião, A. M.; Ribeiro, J. A. Evidence for the presence of excitatory A2 adenosine receptors in the rat hippocampus. Neurosci. Lett. 1992, 138, 41-44.
41. Cunha, R. A.; Johansson, B.; van der Ploeg, I.; Sebastiao, A. M.; Ribeiro, J. A.; Fredholm, B. B. Evidence for functionally important adenosine A2a receptors in the rat hippocampus. Brain Res. 1994, 649, 208-216.
42. Olah, M. E.; Ren, H.; Stiles, G. L. Adenosine receptors: protein and gene structure. Arch. Int. Pharmacodyn. Ther. 1995, 329, 135-150.
43. Fredholm, B. B.; Ijzerman, A. P.; Jacobson, K. A.; Klotz, K. N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 2001, 53, 527-552.
44. Ribeiro, J. A.; Sebastiao, A. M.; de Mendonca, A. Adenosine receptors in the nervous system: pathophysiological implications. Prog. Neurobiol. 2002, 68, 377-392.
45. Xu, K.; Bastia, E.; Schwarzschild, M. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacol. Ther. 2005, 105, 267-310.
46. Fredholm, B. B.; Chen, J. F.; Masino, S. A.; Vaugeois, J. M. Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 385-412.
47. Alexander, S. P.; Mathie, A.; Peters, J. A. Guide to Receptors and Channels (GRAC), 3rd edition. Br. J. Pharmacol. 2008, 153 (Suppl 2), S1-209.
48. Dunwiddie, T. V.; Haas, H. L. Adenosine increases synaptic facilitation in the in vitro rat hippocampus: evidence for a presynaptic site of action. J. Physiol. 1985, 369, 365-377.
49. 1 adenosine receptor agonist-induced activation of phospholipase C in collaboration with thyrotropin. A novel stimulatory mechanism through the cross-talk of two types of receptors. J. Biol. Chem. 1997, 272, 23130-23137.
50. De Mendonça, A.; Almeida, T.; Bashir, Z. I.; Ribeiro, J. A. Endogenous adenosine attenuates long-term depression and depotentiation in the CA1 region of the rat hippocampus. Neuropharmacology 1997, 36, 161-167.
51. Corradetti, R.; Lo Conte, G.; Moroni, F.; Passani, M. B.; Pepeu, G. Adenosine decreases aspartate and glutamate release from rat hippocampal slices. Eur. J. Pharmacol. 1984, 104, 19-26.
52. Muzzolini, A.; Bregola, G.; Bianchi, C.; Beani, L.; Simonato, M. Characterization of glutamate and [3H]D-aspartate outflow from various in vitro preparations of the rat hippocampus. Neurochem. Int. 1997, 31, 113-124.
53. 2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas. Neuroscience 1997, 80, 1171-1185.
54. Augood, S. J.; Emson, P. C. Adenosine A2a receptor mRNA is expressed by enkephalin cells but not by somatostatin cells in rat striatum: a co-expression study. Brain Res. Mol. Brain Res. 1994, 22, 204-210.
55. Svenningsson, P.; Hall, H.; Sedvall, G.; Fredholm, B. B. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse 1997, 27, 322-335.
56. 2A receptor mRNA in the primate striatum. J. Comp. Neurol. 1998, 399, 229-240.
57. Dixon, A. K.; Gubitz, A. K.; Sirinathsinghji, D. J.; Richardson, P. J.; Freeman, T. C. Tissue distribution of adenosine receptor mRNAs in the rat. Br. J. Pharmacol. 1996, 118, 1461-1468.
58. 2A receptors in the rat central nervous system. J. Comp. Neurol. 1998, 401, 163-186.
59. 2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J. Comp. Neurol. 2001, 431, 331-346.
60. Fink, J. S.; Weaver, D. R.; Rivkees, S. A.; Peterfreund, R. A.; Pollack, A. E.; Adler, E. M.; Reppert, S. M. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res. Mol. Brain Res. 1992, 14, 186-195.
61. Ferré, S.; von Euler, G.; Johansson, B.; Fredholm, B. B.; Fuxe, K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. USA 1991, 88, 7238-7241.
62. 2A receptors in dopamine D2 receptor regulation in the rat dopamine-denervated striatum. Eur. J. Neurosci. 2000, 12, 4033-4037.
63. 2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur. J. Pharmacol. 1997, 321, 143-147.
64. Corvol, J. C.; Studler, J. M.; Schonn, J. S.; Girault, J. A.; Herve, D. Galpha(olf) is necessary for coupling D1 and A2a receptors to adenylyl cyclase in the striatum. J. Neurochem. 2001, 76, 1585-1588.
65. 2A receptors. Naunyn Schmiedebergs Arch. Pharmacol. 1999, 359, 295-302.
66. Lopes, L. V.; Cunha, R. A.; Ribeiro, J. A. Cross talk between A(1) and A(2A) adenosine receptors in the hippocampus and cortex of young adult and old rats. J. Neurophysiol. 1999, 82, 3196-3203.
67. Sebastião, A. M.; Ribeiro, J. A. Adenosine A2 receptor-mediated excitatory actions on the nervous system. Prog. Neurobiol. 1996, 48, 167-189.
68. 1 and A2 receptor-mediated responses in the rat hippocampus in vitro. Eur. J. Pharmacol. 1998, 362, 17-25.
69. Lopes, L. V.; Cunha, R. A.; Ribeiro, J. A. Cross-talk between A(1)/A(2A) adenosine receptors in the rat hippocampus and cortex. Brit. J. Pharmacol. 1999, 127, U20-U20.
70. Lopes, L. V.; Cunha, R. A.; Kull, B.; Fredholm, B. B.; Ribeiro, J. A. Adenosine A(2A) receptor facilitation of hippocampal synaptic transmission is dependent on tonic A(1) receptor inhibition. Neuroscience 2002, 112, 319-329.
71. Cunha, R. A.; Ribeiro, J. A. Purinergic modulation of [(3)H]GABA release from rat hippocampal nerve terminals. Neuropharmacology 2000, 39, 1156-1167.
72. 2A receptors enhance GABA transport into nerve terminals by restraining PKC inhibition of GAT-1. J. Neurochem. 2009, 109, 336-347.
73. Rodrigues, R. J.; Canas, P. M.; Lopes, L. V.; Oliveira, C. R.; Cunha, R. A. Modification of adenosine modulation of acetylcholine release in the hippocampus of aged rats. Neurobiol. Aging 2008, 29, 1597-1601.
74. 2A adenosine receptors is PKA-dependent and correlates with increased GluR1 membrane expression. Soc. Neurosci. Abstr. 2008, 42.
75. 2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. J. Neurosci. 2004, 24, 2905-2913.
76. 2A receptors. Hippocampus 2007, 17, 577-585.
77. Nishizaki, T.; Nagai, K.; Nomura, T.; Tada, H.; Kanno, T.; Tozaki, H.; Li, X. X.; Kondoh, T.; Kodama, N.; Takahashi, E.; Sakai, N.; Tanaka, K.; Saito, N. A new neuromodulatory pathway with a glial contribution mediated via A(2a) adenosine receptors. Glia 2002, 39, 133-147.
78. 2A receptors control the extracellular levels of adenosine through modulation of nucleoside transporters activity in the rat hippocampus. J. Neurochem. 2005, 93, 595-604.
79. Fernandez, M.; Svenningsson, P.; Fredholm, B. B. Adaptive changes in adenosine receptors following long-term treatment with the adenosine receptor agonist R-phenylisopropyl adenosine. Life Sci. 1996, 58, 769-776.
80. Cunha, R. A. Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade. Purinergic Signal. 2005, 1, 111-134.
81. 1 and A2a adenosine receptor binding in aged striatum, hippocampus and cortex of the rat. Neuroreport 1995, 6, 1583-1588.
82. Ciruela, F.; Casado, V.; Rodrigues, R. J.; Lujan, R.; Burgueno, J.; Canals, M.; Borycz, J.; Rebola, N.; Goldberg, S. R.; Mallol, J.; Cortes, A.; Canela, E. I.; Lopez-Gimenez, J. F.; Milligan, G.; Lluis, C.; Cunha, R. A.; Ferre, S.; Franco, R. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J. Neurosci. 2006, 26, 2080-2087.
83. Ciruela, F.; Ferre, S.; Casado, V.; Cortes, A.; Cunha, R. A.; Lluis, C.; Franco, R. Heterodimeric adenosine receptors: a device to regulate neurotransmitter release. Cell Mol. Life Sci. 2006, 63, 2427-2431.
84. Ferré, S.; Ciruela, F.; Quiroz, C.; Lujan, R.; Popoli, P.; Cunha, R. A.; Agnati, L. F.; Fuxe, K.; Woods, A. S.; Lluis, C.; Franco, R. Adenosine receptor heteromers and their integrative role in striatal function. ScientificWorldJournal 2007, 7, 74-85.
85. Hosli, E.; Hosli, L. Autoradiographic studies on the uptake of adenosine and on binding of adenosine analogues in neurons and astrocytes of cultured rat cerebellum and spinal cord. Neuroscience 1988, 24, 621-628.
86. Van Calker, D.; Muller, M.; Hamprecht, B. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J. Neurochem. 1979, 33, 999-1005.
87. 2A adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: characterization with radioligand binding and by activation of adenylate cyclase. Mol. Pharmacol. 1992, 41, 352-359.
88. Fredholm, B. B.; Irenius, E.; Kull, B.; Schulte, G. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem. Pharmacol. 2001, 61, 443-448.
89. Kessey, K.; Trommer, B. L.; Overstreet, L. S.; Ji, T.; Mogul, D. J. A role for adenosine A2 receptors in the induction of long-term potentiation in the CA1 region of rat hippocampus. Brain Res. 1997, 756, 184-190.
90. Corset, V.; Nguyen-Ba-Charvet, K. T.; Forcet, C.; Moyse, E.; Chedotal, A.; Mehlen, P. Netrin-1-mediated axon outgrowth and cAMP production requires interaction with adenosine A2b receptor. Nature 2000, 407, 747-750.
91. Lopes, L. V.; Rebola, N.; Pinheiro, P. C.; Richardson, P. J.; Oliveira, C. R.; Cunha, R. A. Adenosine A(3) receptors are located in neurons of the rat hippocampus. Neuroreport 2003, 14, 1645-1648.
92. De, M.; Austin, K. F.; Dudley, M. W. Differential distribution of A3 receptor in rat brain. Soc. Neurosci. Abstr. 1993, 42, 11.
93. Gallo-Rodriguez, C.; Ji, X. D.; Melman, N.; Siegman, B. D.; Sanders, L. H.; Orlina, J.; Fischer, B.; Pu, Q.; Olah, M. E.; van Galen, P. J.; et al. Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists. J. Med. Chem. 1994, 37, 636-646.
94. Costenla, A. R.; Lopes, L. V.; de Mendonca, A.; Ribeiro, J. A. A functional role for adenosine A(3) receptors: modulation of synaptic plasticity in the rat hippocampus. Neurosci. Lett. 2001, 302, 53-57.
95. Zhou, Q. Y.; Li, C.; Olah, M. E.; Johnson, R. A.; Stiles, G. L.; Civelli, O. Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc. Natl. Acad. Sci. USA 1992, 89, 7432-7436.
96. Abbracchio, M. P.; Brambilla, R.; Ceruti, S.; Kim, H. O.; von Lubitz, D. K.; Jacobson, K. A.; Cattabeni, F. G protein-dependent activation of phospholipase C by adenosine A3 receptors in rat brain. Mol. Pharmacol. 1995, 48, 1038-1045.
97. Palmer, T. M.; Gettys, T. W.; Stiles, G. L. Differential interaction with and regulation of multiple G-proteins by the rat A3 adenosine receptor. J. Biol. Chem. 1995, 270, 16895-16902.
98. Ramkumar, V.; Stiles, G. L.; Beaven, M. A.; Ali, H. The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J. Biol. Chem. 1993, 268, 16887-16890.
99. Linden, J. Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol. Sci. 1994, 15, 298-306.
100. Borea, P. A.; Gessi, S.; Bar-Yehuda, S.; Fishman, P. A3 adenosine receptor: pharmacology and role in disease. Handb. Exp. Pharmacol. 2009, 297-327.
101. Pedata, F. P., Sebastião, A. M.; Ribeiro, J. A. Adenosine A3 receptor signalling in the central nervous system. Springer Science: London, New York, 2010; Vol. 194, pp 165-188.
102. 2A receptors in psychiatric disorders. Curr. Pharm. Des. 2008, 14, 1512-1524.
103. Miller, J. P.; Selman, W. R. Deep brain stimulation for depression. J. Neurosurg. 2009, 111, 1207-1208.
104. Bear, R. E.; Fitzgerald, P.; Rosenfeld, J. V.; Bittar, R. G. Neurosurgery for obsessive-compulsive disorder: contemporary approaches. J. Clin. Neurosci. 2010, 17, 1-5.
105. Bekar, L.; Libionka, W.; Tian, G. F.; Xu, Q.; Torres, A.; Wang, X.; Lovatt, D.; Williams, E.; Takano, T.; Schnermann, J.; Bakos, R.; Nedergaard, M. Adenosine is crucial for deep brain stimulationmediated attenuation of tremor. Nat. Med. 2008, 14, 75-80.
106. Green, P. J.; Suls, J. The effects of caffeine on ambulatory blood pressure, heart rate, and mood in coffee drinkers. J. Behav. Med. 1996, 19, 111-128.
107. Loke, W. H. Effects of caffeine on mood and memory. Physiol. Behav. 1988, 44, 367-372.
108. Haskell, C. F.; Kennedy, D. O.; Wesnes, K. A.; Scholey, A. B. Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. Psychopharmacology (Berl) 2005, 179, 813-825.
109. 1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. Eur. J. Neurosci. 2002, 16, 547-550.
110. 1 receptor. Proc. Natl. Acad. Sci. USA 2001, 98, 9407-9412.
111. Ledent, C.; Vaugeois, J. M.; Schiffmann, S. N.; Pedrazzini, T.; El Yacoubi, M.; Vanderhaeghen, J. J.; Costentin, J.; Heath, J. K.; Vassart, G.; Parmentier, M. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 1997, 388, 674-678.
112. Batalha, V. L.; Sebastiao, A. M.; Lopes, L. V. Adenosine receptor levels in the rat hippocampus: Stress-induced changes. Front. Neurosci. 2009, doi: 10.3389/conf.neuro.01.2009.11.123
113. El Yacoubi, M.; Ledent, C.; Parmentier, M.; Costentin, J.; Vaugeois, J. M. The anxiogenic-like effect of caffeine in two experimental procedures measuring anxiety in the mouse is not shared by selective A(2A) adenosine receptor antagonists. Psychopharmacology (Berl) 2000, 148, 153-163.
114. Florio, C.; Prezioso, A.; Papaioannou, A.; Vertua, R. Adenosine A1 receptors modulate anxiety in CD1 mice. Psychopharmacology (Berl) 1998, 136, 311-319.
115. Jain, N.; Kemp, N.; Adeyemo, O.; Buchanan, P.; Stone, T. W. Anxiolytic activity of adenosine receptor activation in mice. Br. J. Pharmacol. 1995, 116, 2127-2133.
116. Boulenger, J. P.; Uhde, T. W.; Wolff, E. A., 3rd; Post, R. M. Increased sensitivity to caffeine in patients with panic disorders. Preliminary evidence. Arch. Gen. Psychiatry. 1984, 41, 1067-1071.
117. Klein, E.; Zohar, J.; Geraci, M. F.; Murphy, D. L.; Uhde, T. W. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects. Biol. Psychiatry. 1991, 30, 973-984.
118. Alsene, K.; Deckert, J.; Sand, P.; de Wit, H. Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 2003, 28, 1694-1702.
119. Hamilton, S. P.; Slager, S. L.; De Leon, A. B.; Heiman, G. A.; Klein, D. F.; Hodge, S. E.; Weissman, M. M.; Fyer, A. J.; Knowles, J. A. Evidence for genetic linkage between a polymorphism in the adenosine 2A receptor and panic disorder. Neuropsychopharmacology 2004, 29, 558-565.
120. Lam, P.; Hong, C. J.; Tsai, S. J. Association study of A2a adenosine receptor genetic polymorphism in panic disorder. Neurosci. Lett. 2005, 378, 98-101.
121. Tsai, S. J.; Hong, C. J.; Hou, S. J.; Yen, F. C. Association study of adenosine A2a receptor (1976C>T) genetic polymorphism and mood disorders and age of onset. Psychiatr. Genet. 2006, 16, 185.
122. Lara, D. R.; Dall'Igna, O. P.; Ghisolfi, E. S.; Brunstein, M. G. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30, 617-629.
123. Ferré, S.; Fredholm, B. B.; Morelli, M.; Popoli, P.; Fuxe, K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 1997, 20, 482-487.
124. Ferré, S. An update on the mechanisms of the psychostimulant effects of caffeine. J. Neurochem. 2008, 105, 1067-1079.
125. Lucas, P. B.; Pickar, D.; Kelsoe, J.; Rapaport, M.; Pato, C.; Hommer, D. Effects of the acute administration of caffeine in patients with schizophrenia. Biol. Psychiatry 1990, 28, 35-40.
126. 1 receptor-mediated modulation of dopamine release in different striatal compartments. J. Neurochem. 2007, 101, 355-363.
127. Laruelle, M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res. Brain Res. Rev. 2000, 31, 371-384.
128. Akhondzadeh, S.; Shasavand, E.; Jamilian, H.; Shabestari, O.; Kamalipour, A. Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. J. Clin. Pharm. Ther. 2000, 25, 131-137.
129. Akhondzadeh, S.; Safarcherati, A.; Amini, H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29, 253-259.
130. Olney, J. W.; Farber, N. B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 1995, 52, 998-1007.
131. Ross, C. A.; Margolis, R. L.; Reading, S. A.; Pletnikov, M.; Coyle, J. T. Neurobiology of schizophrenia. Neuron 2006, 52, 139-153.
132. 1 and A2 receptor agonists significantly prevent the electroencephalographic effects induced by MK-801 in rats. Eur. J. Pharmacol. 1997, 333, 143-146.
133. Sills, T. L.; Azampanah, A.; Fletcher, P. J. The adenosine A1 receptor agonist N6-cyclopentyladenosine blocks the disruptive effect of phencyclidine on prepulse inhibition of the acoustic startle response in the rat. Eur. J. Pharmacol. 1999, 369, 325-329.
134. Hoehn, K.; White, T. D. Evoked release of endogenous adenosine from rat cortical slices by K+ and glutamate. Brain Res. 1989, 478, 149-151.
135. 1 receptors: evidence from knockout mice. Neuropharmacology 2006, 51, 272-282.
136. Chen, Y.; Graham, D. I.; Stone, T. W. Release of endogenous adenosine and its metabolites by the activation of NMDA receptors in the rat hippocampus in vivo. Br. J. Pharmacol. 1992, 106, 632-638.
137. Abekawa, T.; Ito, K.; Koyama, T. Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidineinduced acute increases in glutamate levels in the rat medial prefrontal cortex. Naunyn Schmiedebergs Arch. Pharmacol. 2006, 374, 177-193.
138. 1 receptor activation. Neuroreport 1995, 6, 1097-1100.
139. 2A receptors inhibit the N-methyl-D-aspartate component of excitatory synaptic currents in rat striatal neurons. Eur. J. Pharmacol. 2002, 451, 161-164.
140. 2A adenosine receptors diminishes the reinforcing efficacy of cocaine. Neuropsychopharmacology 2006, 31, 978-987.
141. 2A and dopamine receptors in the locomotor and sensitizing effects of cocaine. Brain Res. 2006, 1077, 67-80.
142. Knapp, C. M.; Foye, M. M.; Cottam, N.; Ciraulo, D. A.; Kornetsky, C. Adenosine agonists CGS 21680 and NECA inhibit the initiation of cocaine self-administration. Pharmacol. Biochem. Behav. 2001, 68, 797-803.
143. Weerts, E. M.; Griffiths, R. R. The adenosine receptor antagonist CGS15943 reinstates cocaine-seeking behavior and maintains selfadministration in baboons. Psychopharmacology (Berl) 2003, 168, 155-163.
144. Baldo, B. A.; Koob, G. F.; Markou, A. Role of adenosine A2 receptors in brain stimulation reward under baseline conditions and during cocaine withdrawal in rats. J. Neurosci. 1999, 19, 11017-11026.
145. Kuzmin, A.; Johansson, B.; Zvartau, E. E.; Fredholm, B. B. Caffeine, acting on adenosine A(1) receptors, prevents the extinction of cocaine-seeking behavior in mice. J. Pharmacol. Exp. Ther. 1999, 290, 535-542.
146. Green, T. A.; Schenk, S. Dopaminergic mechanism for caffeineproduced cocaine seeking in rats. Neuropsychopharmacology 2002, 26, 422-430.
147. 1 receptor in the rat nucleus accumbens. J. Neurochem. 2003, 87, 1478-1484.
148. Manzoni, O.; Pujalte, D.; Williams, J.; Bockaert, J. Decreased presynaptic sensitivity to adenosine after cocaine withdrawal. J. Neurosci. 1998, 18, 7996-8002.
149. Ross, G. W.; Abbott, R. D.; Petrovitch, H.; Morens, D. M.; Grandinetti, A.; Tung, K. H.; Tanner, C. M.; Masaki, K. H.; Blanchette, P. L.; Curb, J. D.; Popper, J. S.; White, L. R. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000, 283, 2674-2679.
150. Ascherio, A.; Zhang, S. M.; Hernan, M. A.; Kawachi, I.; Colditz, G. A.; Speizer, F. E.; Willett, W. C. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. 2001, 50, 56-63.
151. Abbott, R. D.; Ross, G. W.; White, L. R.; Sanderson, W. T.; Burchfiel, C. M.; Kashon, M.; Sharp, D. S.; Masaki, K. H.; Curb, J. D.; Petrovitch, H. Environmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging Study. J. Neurol. 2003, 250 (Suppl 3), III30-39.
152. Kitagawa, M.; Houzen, H.; Tashiro, K. Effects of caffeine on the freezing of gait in Parkinson's disease. Mov. Disord. 2007, 22, 710-712.
153. Chen, J. F.; Sonsalla, P. K.; Pedata, F.; Melani, A.; Domenici, M. R.; Popoli, P.; Geiger, J.; Lopes, L. V.; De Mendonca, A. Adenosine A(2A) receptors and brain injury: Broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. Prog. Neurobiol. 2007, 83, 310-331.
154. Chen, J. F.; Xu, K.; Petzer, J. P.; Staal, R.; Xu, Y. H.; Beilstein, M.; Sonsalla, P. K.; Castagnoli, K.; Castagnoli, N., Jr.; Schwarzschild, M. A. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 2001, 21, RC143.
155. 2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J. Neurosci. 2006, 26, 13548-13555.
156. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 1998, 43, 507-513.
157. Kanda, T.; Jackson, M. J.; Smith, L. A.; Pearce, R. K.; Nakamura, J.; Kase, H.; Kuwana, Y.; Jenner, P. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp. Neurol. 2000, 162, 321-327.
158. 2A receptors and Parkinson's disease. Handb. Exp. Pharmacol. 2009, 589-615.
159. Fernandez, H. H.; Greeley, D. R.; Zweig, R. M.; Wojcieszek, J.; Mori, A.; Sussman, N. M. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat. Disord. 2010, 16, 16-20.
160. Bara-Jimenez, W.; Sherzai, A.; Dimitrova, T.; Favit, A.; Bibbiani, F.; Gillespie, M.; Morris, M. J.; Mouradian, M. M.; Chase, T. N. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003, 61, 293-296.
161. Hauser, R. A.; Hubble, J. P.; Truong, D. D. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003, 61, 297-303.
162. 2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. Drugs Aging 2005, 22, 471-482.
163. 2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann. Neurol. 2008, 63, 295-302.
164. Hauser, R. A.; Shulman, L. M.; Trugman, J. M.; Roberts, J. W.; Mori, A.; Ballerini, R.; Sussman, N. M. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov. Disord. 2008, 23, 2177-2185.
165. 2A receptor antagonists for Parkinson's disease. Expert. Opin. Investig. Drugs 2009, 18, 1619-1631.
166. 2A receptors in Huntington's disease. Prog. Neurobiol. 2007, 81, 331-348.
167. Blum, D.; Hourez, R.; Galas, M. C.; Popoli, P.; Schiffmann, S. N. Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. Lancet Neurol. 2003, 2, 366-374.
168. 1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. J. Neurosci. 2002, 22, 9122-9133.
169. 2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. Neurobiol. Dis. 2007, 28, 197-205.
170. Zuccato, C.; Ciammola, A.; Rigamonti, D.; Leavitt, B. R.; Goffredo, D.; Conti, L.; MacDonald, M. E.; Friedlander, R. M.; Silani, V.; Hayden, M. R.; Timmusk, T.; Sipione, S.; Cattaneo, E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293, 493-498.
171. 2A receptor activation by endogenous adenosine. Neuropharmacology 2008, 54, 924-933.
172. Zuccato, C.; Cattaneo, E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol. 2007, 81, 294-330.
173. Dhaenens, C. M.; Burnouf, S.; Simonin, C.; Van Brussel, E.; Duhamel, A.; Defebvre, L.; Duru, C.; Vuillaume, I.; Cazeneuve, C.; Charles, P.; Maison, P.; Debruxelles, S.; Verny, C.; Gervais, H.; Azulay, J. P.; Tranchant, C.; Bachoud-Levi, A. C.; Durr, A.; Buee, L.; Krystkowiak, P.; Sablonniere, B.; Blum, D. A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease. Neurobiol. Dis. 2009, 35, 474-476.
174. Sawyer, D. A.; Julia, H. L.; Turin, A. C. Caffeine and human behavior: arousal, anxiety, and performance effects. J. Behav. Med. 1982, 5, 415-439.
175. Johnson-Kozlow, M.; Kritz-Silverstein, D.; Barrett-Connor, E.; Morton, D. Coffee consumption and cognitive function among older adults. Am. J. Epidemiol. 2002, 156, 842-850.
176. Santos, C.; Lunet, N.; Azevedo, A.; de Mendonca, A.; Ritchie, K.; Barros, H. Caffeine Intake is Associated with a Lower Risk of Cognitive Decline: A Cohort Study from Portugal. J. Alzheimers Dis. 2010, 20 (Suppl 1), S175-85.
177. Maia, L.; de Mendonca, A. Does caffeine intake protect from Alzheimer's disease? Eur. J. Neurol. 2002, 9, 377-382.
178. Ritchie, K.; Carriere, I.; de Mendonca, A.; Portet, F.; Dartigues, J. F.; Rouaud, O.; Barberger-Gateau, P.; Ancelin, M. L. The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology 2007, 69, 536-545.
179. Eskelinen, M. H.; Ngandu, T.; Tuomilehto, J.; Soininen, H.; Kivipelto, M. Midlife coffee and tea drinking and the risk of latelife dementia: a population-based CAIDE study. J. Alzheimers Dis. 2009, 16, 85-91.
180. Cao, C.; Cirrito, J. R.; Lin, X.; Wang, L.; Verges, D. K.; Dickson, A.; Mamcarz, M.; Zhang, C.; Mori, T.; Arendash, G. W.; Holtzman, D. M.; Potter, H. Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. J. Alzheimers Dis. 2009, 17, 681-697.
181. Arendash, G. W.; Mori, T.; Cao, C.; Mamcarz, M.; Runfeldt, M.; Dickson, A.; Rezai-Zadeh, K.; Tane, J.; Citron, B. A.; Lin, X.; Echeverria, V.; Potter, H. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. J. Alzheimers Dis. 2009, 17, 661-680.
182. Costenla, A. R.; Cunha, R. A.; de Mendonca, A. Caffeine, adenosine receptors, and synaptic plasticity. J. Alzheimers Dis. 2010, 20 (Suppl 1), S25-34.
183. Dall'Igna, O. P.; Fett, P.; Gomes, M. W.; Souza, D. O.; Cunha, R. A.; Lara, D. R. Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp. Neurol. 2007, 203, 241-245.
184. 2A receptors upon sub-chronic restraint stress. Neuroscience 2006, 141, 1775-1781.
185. Liu, H. C.; Hong, C. J.; Liu, T. Y.; Tsai, S. J. Association analysis of adenosine A2a receptor 1976T>C polymorphisms and Alzheimer's disease. Eur. Neurol. 2005, 53, 99-100.
186. 2A receptors in the hippocampus and striatum of the rat. Neuroscience 2005, 132, 893-903.
187. 2A receptors stimulate acetylcholine release from nerve terminals of the rat hippocampus. Neurosci. Lett. 1995, 196, 41-44.
188. Jin, S.; Fredholm, B. B. Electrically-evoked dopamine and acetylcholine release from rat striatal slices perfused without magnesium: regulation by glutamate acting on NMDA receptors. Br. J. Pharmacol. 1997, 121, 1269-1276.
189. De Mendonça, A.; Ribeiro, J. A. Endogenous adenosine modulates long-term potentiation in the hippocampus. Neuroscience 1994, 62, 385-390.
190. Rebola, N.; Coelho, J. E.; Costenla, A. R.; Lopes, L. V.; Parada, A.; Oliveira, C. R.; Soares-da-Silva, P.; de Mendonca, A.; Cunha, R. A. Decrease of adenosine A(1) receptor density and of adenosine neuromodulation in the hippocampus of kindled rats. Eur. J. Neurosci. 2003, 18, 820-828.
191. Lopes, L. V.; Cunha, R. A.; Ribeiro, J. A. Increase in the number, G protein coupling, and efficiency of facilitatory adenosine A(2A) receptors in the limbic cortex, but not striatum, of aged rats. J. Neurochem. 1999, 73, 1733-1738.
192. Rodrigues, R. J.; Almeida, T.; de Mendonca, A.; Cunha, R. A. Interaction between P2X and nicotinic acetylcholine receptors in glutamate nerve terminals of the rat hippocampus. J. Mol. Neurosci. 2006, 30, 173-176.
193. Boison, D. The adenosine kinase hypothesis of epileptogenesis. Prog. Neurobiol. 2008, 84, 249-262.
194. Barraco, R. A.; Swanson, T. H.; Phillis, J. W.; Berman, R. F. Anticonvulsant effects of adenosine analogues on amygdaloidkindled seizures in rats. Neurosci. Lett. 1984, 46, 317-322.
195. 1 receptors are crucial in keeping an epileptic focus localized. Exp. Neurol. 2006, 200, 184-190.
196. Wilz, A.; Pritchard, E. M.; Li, T.; Lan, J. Q.; Kaplan, D. L.; Boison, D. Silk polymer-based adenosine release: therapeutic potential for epilepsy. Biomaterials 2008, 29, 3609-3616.
197. 1 receptor knockout mice develop lethal status epilepticus after experimental traumatic brain injury. J. Cereb. Blood Flow Metab. 2006, 26, 565-575.
198. Dunwiddie, T. V. Adenosine and suppression of seizures. Adv. Neurol. 1999, 79, 1001-1010.
199. McGaraughty, S.; Cowart, M.; Jarvis, M. F.; Berman, R. F. Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors. Curr. Top. Med. Chem. 2005, 5, 43-58.
200. 1 receptor desensitization after focal long-term delivery of adenosine by encapsulated myoblasts. Exp. Neurol. 2005, 193, 53-64.
201. Li, T.; Steinbeck, J. A.; Lusardi, T.; Koch, P.; Lan, J. Q.; Wilz, A.; Segschneider, M.; Simon, R. P.; Brustle, O.; Boison, D. Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants. Brain 2007, 130, 1276-1288.
202. Boison, D. Adenosine-based modulation of brain activity. Curr. Neuropharmacol. 2009, 7, 158-159.
203. Newby, A. C.; Worku, Y.; Holmquist, C. A. Adenosine formation. Evidence for a direct biochemical link with energy metabolism. Adv. Myocardiol., 1985, 6, 273-284.